Collaboration and license agreements (Tables)

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Allocation of total transaction price and unsatisfied transaction price

The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of December 31, 2022 (in thousands):


	Transaction Price Allocated		Transaction Price Unsatisfied
Performance obligations:
Research and development targets	$	61,074	$	25,542
Option rights	6,748		2,502
Total	$	67,822	$	28,044

Schedule of revenue from collaboration agreements

Revenue from collaboration agreements was as follows (in thousands):


	Years Ended December 31,
	2022		2021
Revenue from collaboration agreements:
Roche Agreement	$	4,939	$	19,379
Biogen Agreement	19,214		15,720
Calico Agreement	6,943		10,686
Total revenue from collaboration agreements	$	31,096	$	45,785

Schedule of financial information related to collaboration and license agreements

Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2022 (in thousands):


	Accounts Receivable		Deferred Revenue, Current		Deferred Revenue, Net of Current		Deferred Revenue, Total
Supplemental information:
Roche Agreement	$	417	$	4,649	$	16,895	$	21,544
Biogen Agreement	—		11,427		—		11,427
Calico Agreement	1,056		542		—		542
Total	$	1,473	$	16,618	$	16,895	$	33,513

Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2021 (in thousands):


	Accounts Receivable		Deferred Revenue, Current		Deferred Revenue, Net of Current		Deferred Revenue, Total
Supplemental information:
Roche Agreement	$	1,215	$	5,601	$	17,215	$	22,816
Biogen Agreement	3,000		24,032		6,611		30,643
Calico Agreement	1,501		2,167		542		2,709
Total	$	5,716	$	31,800	$	24,368	$	56,168

Schedule of supplemental financial information related to collaboration and license agreements

Supplemental financial information related to the collaboration and license agreements are (in thousands):


	Years Ended December 31,
	2022		2021
Revenue recognized that was included in the contract liability at the beginning of the period	$	25,412	$	34,363
Revenue recognized from performance obligations fully or partially satisfied in previous periods	518		1,654